Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80521
Name lung non-squamous non-small cell carcinoma
Definition A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung non-squamous non-small cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ALK rearrange Ceritinib lung non-squamous non-small cell carcinoma sensitive detail...
MAP2K1 K57N Trametinib lung non-squamous non-small cell carcinoma predicted - sensitive detail...
FGFR2 Y375C Erdafitinib lung non-squamous non-small cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01631279 Phase Ib/II TH-4000 A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors Terminated USA | NZL 0
NCT02657434 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) Completed USA | NLD | ITA | GBR | FRA | ESP | BEL | AUT | AUS 18
NCT02810457 Phase III Carboplatin + FKB238 + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) Completed USA | ITA | ESP | DEU 20
NCT03083691 Phase II Ipilimumab + Nivolumab BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Completed DEU 0
NCT03267316 Phase Ib/II Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) Active, not recruiting NLD | ESP | DEU | BEL | AUT 6
NCT03293680 Phase II Pembrolizumab Pembrolizumab in Elderly Patients With Advanced Lung Cancer Active, not recruiting ESP 0
NCT03409614 Phase III Cemiplimab + Ipilimumab Cemiplimab Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Active, not recruiting USA | ITA | FRA | AUT 14
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) Recruiting USA | ESP | DEU | CAN | BEL 6
NCT03468426 Phase I BI 836880 + Ezabenlimab A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours Active, not recruiting USA | GBR | FRA | ESP | DEU | AUS 6
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03526887 Phase II Pembrolizumab Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) Completed ESP 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Completed USA 0
NCT03786692 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC Recruiting USA 0
NCT03896074 Phase II Atezolizumab + Bevacizumab Atezolizumab Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) Unknown status ITA 0
NCT03906071 Phase III Docetaxel Nivolumab + Sitravatinib Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 3
NCT03909334 Phase II Osimertinib + Ramucirumab Osimertinib Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03975114 Phase II Durvalumab + Tremelimumab Durvalumab A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) Recruiting ITA 0
NCT03976323 Phase III Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Olaparib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Active, not recruiting USA | NZL | GBR | FRA | ESP | DEU | CAN | AUT | AUS 11
NCT03976375 Phase III Lenvatinib Lenvatinib + Pembrolizumab Docetaxel Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 10
NCT03994393 Phase II Durvalumab + Tremelimumab Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE) Active, not recruiting AUS 1
NCT04027946 Phase II LMB-100 + Pembrolizumab LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT04035486 Phase III Osimertinib Carboplatin + Osimertinib + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Osimertinib + Pemetrexed Disodium A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2) Active, not recruiting USA | GBR | FRA | CAN | AUS 16
NCT04042558 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Pemetrexed Disodium Atezolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Cisplatin + Pemetrexed Disodium A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018) Recruiting FRA 0
NCT04043195 Phase Ib/II Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) Active, not recruiting USA 0
NCT04084717 Phase II Crizotinib Study of Crizotinib for ROS1 and MET Activated Lung Cancer Recruiting CAN 0
NCT04093167 Phase II Pembrolizumab Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC Recruiting USA | CAN 0
NCT04099836 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib Terminated USA 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Completed USA 0
NCT04154956 Phase III SAR408701 Docetaxel SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 19
NCT04163432 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (STAGGER) Recruiting USA 0
NCT04173507 Phase II Avelumab + Talazoparib Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Active, not recruiting USA 0
NCT04181060 Phase III Osimertinib Bevacizumab + Osimertinib Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Recruiting USA 0
NCT04194944 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Selpercatinib Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) Active, not recruiting NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA | CAN 1
NCT04245085 Phase II Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Atezolizumab + Bevacizumab + Pemetrexed Disodium ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung) Active, not recruiting ESP | DEU 3
NCT04262856 Phase II AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) Active, not recruiting USA | CAN | AUS 4
NCT04265534 Phase II Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) Terminated USA 0
NCT04310007 Phase II Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04332367 Phase II Carboplatin + Paclitaxel + Ramucirumab Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance Recruiting USA 0
NCT04351555 Phase III Cisplatin + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib Carboplatin + Pemetrexed Disodium A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 18
NCT04394624 Phase II Ramucirumab + SAR408701 Pembrolizumab + Ramucirumab + SAR408701 Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04) Active, not recruiting USA | ESP 4
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Active, not recruiting USA | FRA 0
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04447118 Phase III Pyrotinib Docetaxel Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUS 6
NCT04470674 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients Withdrawn USA 0
NCT04524689 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701 Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) Active, not recruiting USA | FRA | ESP 5
NCT04538664 Phase III Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT04563338 Phase II Atezolizumab Atezolizumab + Bevacizumab An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) Recruiting CAN 0
NCT04581824 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | FRA | ESP | DEU 7
NCT04619797 Phase II Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL 12
NCT04622774 Phase I IMGC936 First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Completed USA | ITA | ESP 0
NCT04686305 Phase I MEDI5752 + Trastuzumab deruxtecan Trastuzumab deruxtecan Carboplatin + MEDI5752 + Trastuzumab deruxtecan Durvalumab + Pemetrexed Disodium + Trastuzumab deruxtecan Carboplatin + Durvalumab + Trastuzumab deruxtecan Cisplatin + Durvalumab + Trastuzumab deruxtecan Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03) Recruiting USA | NLD | ITA | FRA | ESP | CAN | BEL | AUS 9
NCT04691817 Phase Ib/II Atezolizumab + Tocilizumab Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy Recruiting USA 0
NCT04758949 Phase II Nivolumab FL-101 + Nivolumab FL-101 FL-101 in Surgically Resectable Non-Small Cell Lung Cancer Withdrawn 0
NCT04765059 Phase III Cisplatin + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL) Active, not recruiting USA | ITA | ESP | DEU 2
NCT04772235 Phase I Osimertinib + Repotrectinib Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM) Recruiting ESP 0
NCT04786964 Phase III Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Cosibelimab + Pemetrexed Disodium Carboplatin + Cosibelimab + Pemetrexed Disodium Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO) Terminated NZL 7
NCT04822298 Phase I AMG 160 Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer Terminated USA | AUT | AUS 0
NCT04865250 Phase II Atezolizumab + Carboplatin + Nab-paclitaxel Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP) Recruiting DEU 0
NCT04908111 Phase Ib/II MVA-MAGEA3 ChAdOx1-MAGEA3-NYESO A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 Suspended GBR 0
NCT04914897 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) Active, not recruiting USA | ITA | FRA | ESP | AUS 6
NCT04925986 Phase II Pembrolizumab + Sitravatinib Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Terminated USA 0
NCT04928846 Phase III Telisotuzumab vedotin Docetaxel A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT04956692 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) Active, not recruiting USA | FRA | ESP 13
NCT04958811 Phase II Atezolizumab + Bevacizumab + Tiragolumab Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC Recruiting USA 0
NCT04971187 Phase II Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp Alfa With Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Locally Advanced or Metastatic Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer Terminated USA 0
NCT04988295 Phase III Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 20
NCT04993677 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 A Study of SEA-CD40 Given With Other Drugs in Cancers Active, not recruiting USA | FRA | ESP | DEU | CAN 1
NCT04995523 Phase Ib/II AZD2936 A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01) Active, not recruiting USA | NLD | FRA | ESP | BEL | AUS 8
NCT05017025 Phase Ib/II LY3295668 + Osimertinib Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT05048797 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT 11
NCT05067283 Phase I MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Recruiting USA | NZL | ITA | ESP | CAN | AUS 11
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05118854 Phase II Cisplatin + Pemetrexed Disodium + Sotorasib Carboplatin + Pemetrexed Disodium + Sotorasib A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation Recruiting USA 0
NCT05120349 Phase III Osimertinib A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2) Recruiting USA | ITA | GBR | ESP | DEU | CAN 14
NCT05170204 Phase III Durvalumab Alectinib Pralsetinib Entrectinib A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT05184712 Phase III Carboplatin + Pemetrexed Disodium Ivonescimab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Ivonescimab + Pemetrexed Disodium Phase 3 Clinical Study of AK112 for NSCLC Patients Active, not recruiting 1
NCT05242965 Phase II Sargramostim Sargramostim + STEMVAC A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer Recruiting USA 0
NCT05245071 Phase II SAR408701 Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06) Active, not recruiting USA | ITA | FRA | ESP | BEL 2
NCT05338970 Phase III Patritumab deruxtecan HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT05358548 Phase II Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab ATATcH Alternating Treatment Plans for Advanced Cancer Recruiting USA 0
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05400577 Phase II Sotorasib Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC Withdrawn USA 0
NCT05401110 Phase I Carotuximab + Osimertinib Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer Recruiting USA 0
NCT05403385 Phase II Carboplatin + EOS100850 + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 3
NCT05403554 Phase I NI-1801 A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers Recruiting ITA | FRA 0
NCT05429762 Phase I SAR408701 Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) Terminated USA | FRA | ESP | BEL 1
NCT05469178 Phase Ib/II Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer Recruiting USA 0
NCT05492682 Phase I Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer Recruiting DEU 0
NCT05513703 Phase II Telisotuzumab vedotin A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | FRA | DEU | AUS 4
NCT05557591 Phase II Cemiplimab BNT116 + Cemiplimab A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) Recruiting USA | ESP | DEU 4
NCT05567055 Phase II Capmatinib Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations Withdrawn 0
NCT05601973 Phase II Amivantamab-vmjw + Bevacizumab + Lazertinib AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung) Recruiting NLD | ITA | GBR | FRA | ESP 2
NCT05607550 Phase III Cisplatin + Pemetrexed Disodium Furmonertinib Carboplatin + Pemetrexed Disodium Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | AUS 11
NCT05650879 Phase I ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) Recruiting USA | ITA | FRA | ESP | AUS 2
NCT05652868 Phase I MYTX-011 Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Recruiting USA | GBR | ESP | AUS 2
NCT05668988 Phase III Sunvozertinib Carboplatin + Pemetrexed Disodium A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 6
NCT05689671 FDA approved Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Nab-paclitaxel Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE) Recruiting DEU 0
NCT05692999 Phase III Pembrolizumab + Pemetrexed Disodium Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse) Recruiting FRA 0
NCT05703555 Phase II SAR408701 INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION) Withdrawn NLD 0
NCT05704634 Phase I Cemiplimab + Sarilumab A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. Recruiting USA 0
NCT05746481 Phase II Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases Recruiting USA 0
NCT05769959 Phase Ib/II RO7515629 Study of RO7515629 in Participants With HLA-G Positive Solid Tumors Terminated USA 0
NCT05800015 Phase II Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Recruiting USA | CAN | AUS 5
NCT05801029 Phase II Amivantamab-vmjw + Osimertinib A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA) Recruiting CAN 6
NCT05865990 Phase II Patritumab deruxtecan HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) Recruiting ESP | AUT 0
NCT05882734 Phase Ib/II Cemiplimab + M1774 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) Recruiting USA | ITA | FRA | ESP | DEU | BEL 2
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05920356 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Sotorasib A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 25
NCT05973773 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Zipalertinib Carboplatin + Pemetrexed Disodium + Zipalertinib Pemetrexed Disodium Cisplatin + Pemetrexed Disodium + Zipalertinib REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 7
NCT06003075 Phase II Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab Induction Chemo-Nivo in Unresectable Stage III NSCLC Recruiting USA 0
NCT06008093 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON) Recruiting USA 0
NCT06074588 Phase III Docetaxel SKB264 Pemetrexed Disodium Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Recruiting USA | GBR | CAN | AUS 10
NCT06119581 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT06151574 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium BI 1810631 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Recruiting USA | NLD | GBR | FRA | ESP | DEU | BEL | AUS 12
NCT06170788 Phase III Pembrolizumab + SKB264 Pembrolizumab Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >= 50% (MK-2870-007) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 11
NCT06236438 Phase II ABBV-151 + Budigalimab + Cisplatin + Pemetrexed Disodium Budigalimab + Carboplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ABBV-151 + Budigalimab + Carboplatin + Pemetrexed Disodium ABBV-151 + Budigalimab + Pemetrexed Disodium Budigalimab + Cisplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4) Recruiting USA | AUS 3
NCT06244485 Phase I DS-3201b + Trastuzumab deruxtecan Datopotamab deruxtecan + DS-3201b A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors Recruiting USA 1
NCT06279728 Expanded access Datopotamab deruxtecan Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients Available USA | ESP | AUT 0
NCT06305754 Phase III Carboplatin + Pemetrexed Disodium SKB264 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) Recruiting USA 3
NCT06312137 Phase III Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Recruiting USA 7
NCT06322693 Phase I Cobolimab + Docetaxel Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Docetaxel + Dostarlimab-gxly Cobolimab + Dostarlimab-gxly Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cobolimab + Nivolumab A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) Recruiting USA | ESP 1
NCT06330064 Phase II Ifinatamab deruxtecan A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors Recruiting USA 0
NCT06348199 Phase III Pembrolizumab Carboplatin + Pemetrexed Disodium A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting ESP | DEU 6
NCT06350097 Phase III Osimertinib Datopotamab deruxtecan + Osimertinib Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14) Recruiting ITA | ESP | DEU | CAN | AUS 4
NCT06357533 Phase III Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >/= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) Recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT06396065 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Ivonescimab + Paclitaxel Phase III Study of AK112 for NSCLC Patients Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT06401824 Phase II Bevacizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases Not yet recruiting NLD 0
NCT06448754 Phase II Carboplatin + MEDI5752 + Pemetrexed Disodium Volrustomig Priming Regimens Exploratory Phase II Platform Study (eVOLVE-01) Not yet recruiting USA | ITA | FRA | ESP | CAN 6
NCT06452277 Phase III BAY2927088 Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02) Not yet recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 25
NCT06472245 Phase III OSE 2101 Docetaxel Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) Not yet recruiting USA 0